Application of dental pulp stem cells in preparation of medicine for treating multiple sclerosis

A technology of multiple sclerosis and dental pulp stem cells, applied in the field of biomedicine, to achieve the effect of easy acquisition, inhibition of central inflammation, and reduction of spinal cord demyelination lesions
CN114869913APending Publication Date: 2022-08-09BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Current Assignee / Owner
BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
Publication Date
2022-08-09

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of dental pulp stem cells in preparation of a medicine for treating multiple sclerosis. The embodiment of the invention provides application of dental pulp stem cells in preparation of a medicine for treating multiple sclerosis. The dental pulp stem cells are simple and convenient to obtain, easy to amplify in vitro and high in multiplication capacity, and have clinical application advantages compared with other human body mesenchymal stem cells. Research shows that the dental pulp stem cells can obviously reduce EAE mouse spinal cord demyelination focus, reduce the injury area around the ventricle and reduce demyelination injury; in addition, immune cell infiltration in the brain can be obviously reduced, T cell infiltration is reduced, and central inflammation is inhibited.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of dental pulp stem cells in preparing drugs for multiple sclerosis. Background technique

[0002] Multiple sclerosis (MS) is an autoimmune disease involving the central nervous system mediated by activated CD4+ T cells. Its main immune mechanism is that peripheral lymphocytes enter the CNS and cause irreversible inflammation of nerve fibers. Demyelinating changes and axonal damage. Traditional drugs for the treatment of MS include Copaxone, interferon beta, etc., which have mild side effects but not significant efficacy. Newly approved drugs by the U.S. FDA, such as Natalizumab and Fingolimod, have significant effects on MS. These drugs reduce neuroinflammation by inhibiting lymphocyte adhesion or migration, but may cause progressive neuroinflammation. Serious complications such as multifocal leukoencephalopathy and sudden cardiac death....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More